全文获取类型
| 收费全文 | 3356篇 |
| 免费 | 154篇 |
| 国内免费 | 9篇 |
专业分类
| 财政金融 | 554篇 |
| 工业经济 | 186篇 |
| 计划管理 | 616篇 |
| 经济学 | 793篇 |
| 综合类 | 259篇 |
| 运输经济 | 39篇 |
| 旅游经济 | 38篇 |
| 贸易经济 | 418篇 |
| 农业经济 | 278篇 |
| 经济概况 | 338篇 |
出版年
| 2025年 | 18篇 |
| 2024年 | 30篇 |
| 2023年 | 67篇 |
| 2022年 | 38篇 |
| 2021年 | 57篇 |
| 2020年 | 117篇 |
| 2019年 | 111篇 |
| 2018年 | 113篇 |
| 2017年 | 122篇 |
| 2016年 | 118篇 |
| 2015年 | 119篇 |
| 2014年 | 225篇 |
| 2013年 | 387篇 |
| 2012年 | 189篇 |
| 2011年 | 276篇 |
| 2010年 | 202篇 |
| 2009年 | 197篇 |
| 2008年 | 224篇 |
| 2007年 | 191篇 |
| 2006年 | 143篇 |
| 2005年 | 112篇 |
| 2004年 | 91篇 |
| 2003年 | 62篇 |
| 2002年 | 44篇 |
| 2001年 | 49篇 |
| 2000年 | 42篇 |
| 1999年 | 31篇 |
| 1998年 | 24篇 |
| 1997年 | 19篇 |
| 1996年 | 22篇 |
| 1995年 | 16篇 |
| 1994年 | 12篇 |
| 1993年 | 13篇 |
| 1992年 | 7篇 |
| 1991年 | 5篇 |
| 1990年 | 7篇 |
| 1989年 | 4篇 |
| 1988年 | 3篇 |
| 1987年 | 1篇 |
| 1986年 | 1篇 |
| 1984年 | 2篇 |
| 1983年 | 5篇 |
| 1982年 | 2篇 |
| 1979年 | 1篇 |
排序方式： 共有3519条查询结果，搜索用时 15 毫秒
41.
Elias J. Jabbour Martin F. Mendiola Melissa Lingohr-Smith Jay Lin Dinara Makenbaeva 《Journal of medical economics》2013,16(11):1113-1118
AbstractObjective: To develop an economic model to evaluate changes in healthcare costs driven by restricting usage of branded tyrosine kinase inhibitors (TKIs) through substitution with generic imatinib among chronic myeloid leukemia (CML) patients in a typical Oncology Care Model (OCM) practice, and examine the impact on Performance-Based Payment (PBP) eligibility.Methods: An Excel-based economic model of an OCM practice with 1,000 cancer patients during a 6-month episode of care was developed. Cancer types and proportions of patients treated in the practice were estimated from an OCM report. All-cause healthcare costs were obtained from published literature. It was assumed that if a practice restricts usage of branded TKIs for newly-diagnosed CML patients, 80% of the market share of branded imatinib and 50% of the market shares of 2nd-gen TKIs would shift to generic imatinib. Among established TKI-treated patients, it was assumed that 80% of the market share of branded imatinib and no patients treated with 2nd-gen TKIs would shift to the generic.Results: Four CML patients were estimated for a 1,000-cancer patient OCM practice with a total baseline healthcare cost of $51,345,812 during a 6-month episode. If the practice restricts usage of branded TKIs, the shift from 2nd-gen TKIs to generic imatinib would reduce costs by $12,970, while shifting from branded to generic imatinib lowers costs by $25,250 during a 6-month episode. Minimum reductions of $3,013,832 in a one-sided risk model and $2,372,010 in a two-sided risk model are required for PBP eligibility; the shift from 2nd-gen TKIs to generic imatinib would account for 0.4% and 0.5% of the savings required for a PBP, respectively.Conclusions: This analysis indicates that the potential cost reduction associated with restricting branded TKI usage among CML patients in an OCM setting will represent only a small proportion of the cost reduction needed for PBP eligibility. 相似文献
42.
北京公交的运营成本过高是北京市公交发展中的一个比较突出的问题,而且目前北京公交缺乏科学、精确的运营成本测算方法与体系。为解决相关问题,应该结合国内外相关研究与调研资料对北京市公交运营成本的构成体系进行确定与分析,并运用作业成本法对北京市公交运营成本展开测算研究。 相似文献
43.
《Journal of medical economics》2013,16(1-4):143-153
SummaryThis study provides economic information on the costs of obesity in the UK using a modified method of attributable risk to establish the full resource implications of treating obesity and associated diseases. Prevalence estimates of obesity, defined as a Body Mass Index (BMI) greater than 30 kg/m2, together with estimates of the risk of obesity-related diseases relative to a BMI range close to ideal, are used as the basis of the costing. The total costs of treating obesity and its related diseases are estimated at £355 million (in 1995 prices). The total costs of treating obesity directly, estimated at £3.8 million, are dominated by the costs arising from the treatment of attributable diseases, estimated at £351 million. 相似文献
44.
Simon Thomas Robert Repetto Daniel Dias 《Corporate Governance: An International Review》2007,15(3):421-426
This paper introduces a new measure, based on a study by Trucost and Dr Robert Repetto, combining external environmental costs with established measures of economic value added, and demonstrates how this measure can be incorporated into financial analysis. We propose that external environmental costs are relevant to all investors: universal investors are concerned about the scale of external costs whether or not regulations to internalise them are likely; mainstream investors need to understand external costs as an indication of future regulatory compliance costs; and SRI investors need to evaluate companies on both financial and social performance. The paper illustrates our new measure with data from US electric utilities and illustrates how the environmental exposures of different fund managers and portfolios can be compared. With such measures fund managers can understand and control portfolio‐wide environmental risks, demonstrate their environmental credentials quantitatively and objectively and compete for the increasing number of investment mandates that have an environmental component. 相似文献
45.
46.
Ingrid Stein 《The German Economic Review》2015,16(3):367-389
This study analyzes the impact of bank relationships on a firm's borrowing costs. We find that a firm's borrowing costs decrease with relationship strength, proxied by the share of bank debt provided by the lender. Borrowing costs, however, rise with relationship length. While the increase over time is weak on average, bank‐dependent borrowers face a substantial premium after several relationship years. Switching the lender initially leads to only a small price discount on average. However, the discount is considerable for borrowers that switch and had a strong relationship with their previous lender. Our results suggest that close lending relationships lead to benefits for the firm, but may also imply hold‐up costs in the long term. 相似文献
47.
文章从成本的角度探讨可持续发展对企业成本理念的要求,认为要适应可持续发展的要求,必须树立四维成本系统理念,即产品成本、资本成本、代理成本和环境成本.文章逐个分析了企业的四维成本,然后基于人本观提出了如何构建四维成本体系. 相似文献
48.
服务业是未来吸收劳动力的主要途径。文章主要通过聚类分析将浙江省各县市按照本地劳动力在服务业的分配分成几类,然后再分别对这几类的数据进行主成分分析,找出它们在服务业领域的比较优势,进而根据分析结果得出结论。浙江省的各个县市在服务业发展方面都具有各自的潜力与主要发展方向,未来浙江省的三大产业比重会调整到“三、二、一”的局面,服务业在吸收劳动力方面将发挥更加巨大的作用。 相似文献
49.
《Journal of medical economics》2013,16(1-4):103-134
SummaryA variety of economic studies have been carried out in Europe, North America and Australia. Risperidone is dominant over haloperidol, providing both an improvement in patient benefit and decreasing direct medical costs. These effects are most marked in patients who continue risperidone treatment. Treatment failures need more study, but the costs of therapeutic trial are low enough to recommend risperidone in preference to conventional antipsychotics for patients requiring new or alternative treatment for schizophrenia.Much of the evidence for the economic benefits of risperidone comes from studies with historical controls in treatment resistant or treatment intolerant patients. The biggest contributor to the economic impact of risperidone is the reduction in hospital stay resulting from treatment with the drug. More long-term work is required with parallel control groups and also with less severely ill patients. 相似文献
50.
Jalpa A. Doshi Pengxiang Li Sunita Desai Steven C. Marcus 《Journal of medical economics》2017,20(12):1252-1260